Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress | Synapse
March 3, 2026
Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress
Key Points
Enhanced outcomes are reliant on identifying predictive biomarkers for triple negative breast cancer (TNBC).
Current strategies aim to refine individualized therapy plans for TNBC to improve patient outcomes.
Analysis of the current progress reveals gaps in effective signalling pathways and inhibitor usage in TNBC.
Future efforts may enable better tailored treatments, though more research is crucial to validate these strategies.
Abstract
To significantly enhance outcomes for TNBC patients, future research must concentrate on identifying predictive biomarkers and refining individualized therapy plans.